- Home
- ATHA vs ZDAI Comparison
ATHA vs ZDAI Comparison
Compare ATHA & ZDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- ZDAI
- Stock Information
- Founded
- ATHA 2011
- ZDAI 2022
- Country
- ATHA United States
- ZDAI Hong Kong
- Employees
- ATHA N/A
- ZDAI N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- ZDAI General Bldg Contractors - Nonresidential Bldgs
- Sector
- ATHA Health Care
- ZDAI Consumer Discretionary
- Exchange
- ATHA Nasdaq
- ZDAI Nasdaq
- Market Cap
- ATHA 16.1M
- ZDAI 14.8M
- IPO Year
- ATHA 2020
- ZDAI 2024
- Fundamental
- Price
- ATHA $4.11
- ZDAI $0.42
- Analyst Decision
- ATHA
- ZDAI
- Analyst Count
- ATHA 0
- ZDAI 0
- Target Price
- ATHA N/A
- ZDAI N/A
- AVG Volume (30 Days)
- ATHA 27.3K
- ZDAI 2.2M
- Earning Date
- ATHA 11-06-2025
- ZDAI 11-18-2025
- Dividend Yield
- ATHA N/A
- ZDAI N/A
- EPS Growth
- ATHA N/A
- ZDAI N/A
- EPS
- ATHA N/A
- ZDAI N/A
- Revenue
- ATHA N/A
- ZDAI $19,275,673.00
- Revenue This Year
- ATHA N/A
- ZDAI N/A
- Revenue Next Year
- ATHA N/A
- ZDAI N/A
- P/E Ratio
- ATHA N/A
- ZDAI N/A
- Revenue Growth
- ATHA N/A
- ZDAI 43.16
- 52 Week Low
- ATHA $2.20
- ZDAI $0.37
- 52 Week High
- ATHA $8.26
- ZDAI $107.36
- Technical
- Relative Strength Index (RSI)
- ATHA 59.40
- ZDAI 34.89
- Support Level
- ATHA $3.95
- ZDAI $0.45
- Resistance Level
- ATHA $4.50
- ZDAI $0.57
- Average True Range (ATR)
- ATHA 0.24
- ZDAI 0.04
- MACD
- ATHA -0.05
- ZDAI -0.01
- Stochastic Oscillator
- ATHA 55.81
- ZDAI 9.63
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About ZDAI Primega Group Holdings Limited Ordinary Shares
DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.